That's the name of this column by consumer reporter David Lazarus.
Category Archives: Uncategorized
Ars Technica asks this question amid concerns that the move may have motivated by contributions from the healthcare company whose poor track record prompted the drafting of standards in the first place: [A] 2014 medical review and a June 2015 report by CNN, which found that one particular medical facility, St. Mary’s Medical Center and Palm Beach […]
A slate of five candidates running for Harvard's governing board thinks Harvard's endowment is big enough that it can afford to great free tuition for all undergrads. The candidates — an interesting left-right alliance, including Ralph Nader on the left and four opponents of affirmative action on the right – also raise the concern that the current admission […]
The Times reported last week: With automakers and technology companies rushing to develop self-driving cars, the Obama administration on Thursday pledged to expedite regulatory guidelines for autonomous vehicles and invest in research to help bring them to market. … “We are bullish on autonomous vehicles,” [Transportation Secrecy Anthony] Foxx said. “The actions we are taking […]
Over the past day, we have seen lots of articles on yesterday's decision in Campbell-Ewald v. Gomez. Our own coverage is here. Most simply describe the decision, but here are a few that add some commentary: A nice editorial in The New York Times. Coverage in The Wall Street Journal. Analysis from Howard Wasserman at […]
In a much-anticipated ruling, the Supreme Court today held that a class-action defendant cannot moot a plaintiff’s case by making a pre-class-certification offer of judgment that would satisfy the individual plaintiff’s personal claims but not those of the class. The decision in Campbell-Ewald Co. v. Gomez, holds that such an offer does not moot the […]
The Washington Post reports: Goldman Sachs said Thursday it will pay roughly $5 billion to settle federal and state probes of its role in the sale of shoddy mortgages in the years leading to the housing bubble and subsequent financial crisis. Coming nearly eight years after the crisis, the settlement is by far the largest […]
by Paul Alan Levy A few years ago, Gordon Austin, a Georgia dentist from the small town of Carrollton, about 50 miles west of Atlanta, was indicted on multiple charges stemming in part from Medicare fraud and in part for a series of incidents in which he beat patients with a dental instrument. According to […]
Gerrymandering — the drawing of district lines for the purpose of giving one candidate or party an electoral advantage — dates back to the Founding. (It was named for Elbridge Gerry, a signer of the Declaration of Independence and later Vice President under James Madison.) It's alive and well today, and as President Obama pointed out […]
The Federal Trade Commission reports that pharmaceutical companies entered into substantially fewer potential pay-for-delay patent dispute settlements in fiscal year 2014. Under such settlements, brand-name drug companies pay generic companies to delay entry of less costly drugs onto the market. In FTC v. Actavis (2013), the U.S. Supreme Court held that a brand-name drug manufacturer’s payment […]